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Abstract
Objective
The aims of this study were (1) to describe the incidence of autoimmune encephalitis (AIE)
and acute disseminated encephalomyelitis (ADEM) in children, (2) to validate the currently
used clinical criteria to diagnose AIE, and (3) to describe pitfalls in the diagnosis of pediatric
autoimmune (AI) and inﬂammatory neurologic disorders.
Methods
This study cohort consists of 3 patient categories: (1) children with antibody-mediated AIE
(n = 21), (2) children with ADEM (n = 32), and (3) children with suspicion of an AI etiology of
their neurologic symptoms (n = 60). Baseline and follow-up clinical data were used to validate
the current guideline to diagnose AIE. In addition, patient ﬁles and ﬁnal diagnoses were
reviewed.
Results
One-hundred three of the 113 included patients fulﬁlled the criteria of possible AIE. Twenty-
one children had antibody-mediated AIE, of whom 19 had anti-N-methyl-D-aspartate receptor
(NMDAR), 1 had anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, and 1
had anti–leucine-rich glioma-inactivated protein 1 encephalitis. Finally, 34 children had ADEM,
and 2 children had Hashimoto encephalopathy. Mean incidence rates were 1.54 children/
million (95% CI 0.95–2.35) for antibody-mediated AIE and 2.49 children/million (95% CI
1.73–3.48) for ADEM. Of the other 48 children, treating physicians’ diagnoses were reviewed.
In 22% (n = 6) of children initially diagnosed as having an AI/inﬂammatory etiology (n = 27),
no support for AI/inﬂammation was found.
Conclusion
Besides anti-NMDAR encephalitis and ADEM, other AIEs are rare in children. The current
guideline to diagnose AIE is also useful in children. However, in children with nonspeciﬁc
symptoms, it is important to review data critically, to perform complete workup, and to consult
specialized neuroinﬂammatory centers.
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Autoimmune encephalitis (AIE) has expanded the already
comprehensive list of pediatric neuroinﬂammatory disorders
of the CNS. Anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis and acute disseminated encephalomyelitis
(ADEM) are the most frequently described cause of AIE in
children,1–4 and disease courses have been studied in detail,
including treatment responses, functional recovery,1,4 and
long-term neuropsychological outcome.5
Next to anti-NMDAR, other neuronal antibodies have been
described only sporadically in children,6–8 whereas in adults,
reported incidence of these antibodies has increased
dramatically.9,10 This could indicate that besides anti-
NMDAR encephalitis, neuronal antibodies occur less fre-
quent in children or that these syndromes are unrecognized.
In 2016, Graus et al.11 have described criteria to diagnose
antibody-mediated AIE, ADEM, and other related autoimmune
(AI) encephalitides, including Bickerstaﬀ brainstem encephali-
tis, Hashimoto encephalopathy, and autoantibody-negative
(seronegative) AIE, in adults and in children. These criteria
allow physicians to start ﬁrst-line immunotherapy in patients
with typical limbic encephalitis or probable anti-NMDAR en-
cephalitis before deﬁnite antibody diagnosis. As already stated
by the authors, the criteria should be used with caution in
children because the diﬀerential diagnosis is more widespread.
This prospective, observational, cohort study describes the
incidence of pediatric antibody-mediated AIE and ADEM in
the Netherlands since 2015. In addition, the diagnostic criteria
of Graus et al.11 are validated using data of prospectively
collected cohorts of children with AIE, ADEM, and children
with neurologic symptoms and suspicion of an autoimmune
etiology (AE). Finally, we describe pitfalls in the diagnosis of
pediatric AI and inﬂammatory neurologic disorders.
Methods
Patients
This study cohort contains data of 3 patient groups, included
between January 2015 and December 2018 in the Nether-
lands. The ﬁrst group consists of all Dutch children, aged 0–18
years, diagnosed with antibody-mediated (deﬁnite) AIE.
Antibodies were detected in serum and CSF, using com-
mercial cell-based assays (CBAs; Euroimmun, Lu¨beck,
Germany). Antibodies were conﬁrmed with immunohisto-
chemistry. All children were included after diagnosis and are
being followed prospectively since. The second group consists
of all Dutch children with ADEM diagnosed according to the
International Pediatric Multiple Sclerosis Study Group
(IPMSSG) criteria.12 who were prospectively included in the
nationwide, multicenter PROUD kids study.13 The third
group consists of children with a suspected AE of their neu-
rologic symptoms. These children were prospectively in-
cluded in the observational, multicenter, “Children’s
Autoimmunity Related to Neuropsychiatric symptoms,
Chorea and Epilepsy” (CHANCE) study. The CHANCE
study was a multicenter study, with national accrual, but no
means to be complete. Inclusion criteria were age below 18
years at symptom onset and one of the following clinical
phenotypes: (1) limbic encephalitis, (2) new-onset status
epilepticus, (3) acute encephalopathy, or (4) neuropsychiatric
symptoms combined with symptoms of basal ganglia dys-
function. All serum samples, and if available CSF samples,
were screened for neuronal antibodies using immunohisto-
chemistry14 and CBAs (Euroimmun, Lu¨beck, Germany).
Questionable or positive samples were tested with confor-
mational laboratory techniques, including live hippocampal
neurons,15 in-house CBAs, and ELISA. Antithyroid auto-
antibodies (TPO) were detected by ﬂuorescence enzyme
immunoassay on the Phadia 250 system using EliA according
to the manufacturer’s instructions (Thermo Fisher Scientiﬁc,
Freiburg, Germany).
Data about medical history, disease course, treatment
responses, and ﬁnal diagnoses were collected. Data were
collected from interviews with patients, from treating physi-
cians, or were retrieved from patient ﬁles.
Definitions
The criteria of Graus et al.11 were used to deﬁne possible AIE,
deﬁnite AI limbic encephalitis, probable anti-NMDAR en-
cephalitis, Bickerstaﬀ brainstem encephalitis, Hashimoto en-
cephalopathy, and seronegative but probable AIE. The
IPMSSG criteria12 were used to deﬁne ADEM.
Final etiology was classiﬁed as (1) Deﬁnite AIE, including
children with antibody-mediated AIE and ADEM. (2) Prob-
able AIE, according to the diagnostic criteria.11 This category
consisted of children with ADEMwithout follow-up MRI and
of children with Hashimoto encephalopathy. (3) Possible
Glossary
ADEM = acute disseminated encephalomyelitis; AE = autoimmune etiology; AI = autoimmune; AIE = autoimmune
encephalitis; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor;CBA = cell-based assay;CHANCE =
Children’s Autoimmunity Related to Neuropsychiatric symptoms, Chorea and Epilepsy; FBDS = faciobrachial dystonic
seizures; GAD65 = glutamic acid decarboxylase 65; HSVE = herpes simplex virus encephalitis; IPMSSG = International
Pediatric Multiple Sclerosis Study Group; ivMP = IV methylprednisolone; LGI1 = leucine-rich glioma-inactivated protein 1;
MOG = myelin oligodendrocyte glycoprotein; NMDA receptor = N-methyl-D-aspartate receptor; TPO = thyroid
autoantibodies.
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AE/inﬂammatory, included children not fulﬁlling any of the
diagnostic criteria panels, but with support for autoimmunity or
inﬂammation. This category consisted partially of children with
clinically deﬁned acquired AE/inﬂammatory disorders, such as
Rasmussen encephalitis or Sydenham chorea, and partially of
children with MRI or CSF abnormalities pointing toward an
AE/inﬂammatory etiology (pleocytosis, elevated protein, or
oligoclonal bands in CSF, and MRI lesions in the temporal
lobe), with exclusion of other causes, and not fulﬁlling the criteria
of seronegative AIE.11 (4)Unknown etiology and no support for
AE/inﬂammatory, including children without MRI or CSF ab-
normalities pointing toward and AE/inﬂammatory etiology. (5)
Other diagnosis and no support for AE/inﬂammatory. R.F.N.,
M.J.T., andM.A.A.M.d.B. reviewed follow-up etiologies. Deﬁnite
diagnoses were determined by consensus.
Standard protocol approvals, registrations,
and patient consents
The Institutional Review Board of the Erasmus MC Univer-
sity Medical Center approved the study protocol (MEC-
2014-048; MEC-2005-247). Informed consent was obtained
from all parents and additionally from children aged 12–17
years at inclusion.
Statistics
The annual incidence rate (from 2015 to 2018) was calculated
with 95% CIs, assuming a Poisson distribution. Available data
of the Dutch pediatric population were used (StatLine;
statline.cbs.nl/statweb/). Comparisons were performed using
the χ2 test or the Kruskal-Wallis test.
Data availability
Any data not published in this article are available at the
Erasmus MC University Medical Center. Patient-related data
will be shared on request from any qualiﬁed investigator,
maintaining anonymization of the individual patients.
Results
Patient characteristics
We included 113 patients. Twenty-one patients had deﬁnite
AIE (19%), including 19 (90%) children with anti-NMDAR
encephalitis. Among them, 12 had an idiopathic etiology
(63%), 6 children recently had herpes simplex virus encephalitis
(HSVE; 32%), and 1 girl had an ovarian teratoma (5%) detected
shortly after disease onset. The other 2 children with neuronal
antibodies had anti–leucine-rich glioma-inactivated protein 1
(LGI1) encephalitis (n = 1; 5%) and anti–α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) encepha-
litis (n = 1; 5%). Thirty-two children diagnosed with ADEM
(28%) were included from the PROUD kids cohort. The other
60 patients (53%) were included from the CHANCE study.
Incidence
The annual incidence rates of antibody-mediated AIE and
ADEM of 4 consecutive years (2015–2018) are shown in
table 1. Mean incidence rates were 1.54 children/million
(95% CI 0.95–2.35) and 2.49 children/million (95% CI
1.73–3.48) for AIE and ADEM, respectively.
Validation of AIE criteria
Of all 113 patients included, 103 (89%) fulﬁlled the criteria of
possible AIE (ﬁgure 1). Demographical data are described in
table 2. Children with AIE were more often female (p =
0.023), and children with ADEM were younger (p < 0.0001).
Ten patients included in the CHANCE cohort did not fulﬁll
the criteria and were excluded because of the absence of
working memory deﬁcits or psychiatric symptoms (n = 6) or
because of the longer duration of symptoms (n = 4). These 10
children had epilepsy without additional symptoms (n = 4),
psychiatric disorders (n = 3), mild encephalopathy with re-
versible lesion in the splenium (n = 1), Niemann-Pick disease
type C (n = 1), or Rasmussen encephalitis without epilepsy
(n = 1).
Of the 103 children shown in the ﬂowchart, 1 child had def-
inite limbic encephalitis according to the criteria (ﬁgure e-1,
links.lww.com/NXI/A197). This was a 9-year old boy who
presented with tonic-clonic seizures originating in the left
temporal lobe, followed by refractory status epilepticus. He
was treated with valproic acid, midazolam, and phenytoin.
After status epilepticus, he developed faciobrachial dys-
tonic seizures (FBDS)16 and hyperactive behavior. He was
considered to have anti-LGI1 encephalitis, later conﬁrmed
in his serum and CSF. He was treated with IV methyl-
prednisolone (ivMP). Because of ongoing FBDS, he was
treated again with ivMP and additionally with mycophe-
nolate mofetil, which led to seizure freedom and complete
recovery.
The brain MRI showed demyelinating features in 34 children
(33%). In all these children, encephalopathy and other
symptoms appeared reversible. In 22/34 children, the brain
MRI was repeated, and in none of them, new lesions were
visible. These children were diagnosed as having deﬁnite
ADEM (22/103; 21%). In 31/34, myelin oligodendrocyte
glycoprotein (MOG) antibodies were tested. Twelve of 31
(39%) ADEM children were MOG positive, 4 children had
Table 1 Annual incidence of pediatric AIE and ADEM
Year
AIE—incidence
children/million
(95%-CI)
ADEM—incidence
children/million
(95% CI)
No. of Dutch
pediatric
inhabitants
2015 1.46 (0.47–3.40) 2.62 (1.20–4.98) 3.429.193
2016 1.76 (0.64–3.82) 2.05 (0.82–4.22) 3.416.581
2017 1.76 (0.65–3.84) 3.23 (1.16–5.78) 3.404.098
2018 1.18 (0.32–3.02) 2.07 (0.83–4.26) 3.386.096
2015–2018 1.54 (0.95–2.35) 2.35 (1.61–3.31) 3.408.992
Abbreviations: AIE = autoimmune encephalitis, ADEM = acute disseminated
encephalomyelitis.
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Figure 1 Flowchart showing the validation of the diagnostic criteria of AIE
aAccording to the International Pediatric Multiple Sclerosis Study Group criteria. bIn 21 of the 22 patients without new lesions on the second MRI anti–myelin
oligodendrocyte glycoprotein (MOG) was tested; in 8/21, antibodies were present (38%). cIn 10 of the 12 patients who had no follow-up MRI, anti-MOG was
tested, of them 40% (n = 4) tested positive. dOf whom, 8 had an idiopathic etiology, and 3 recently had herpes simplex virus encephalitis. In blue: probable
diagnosis, first-line immunotherapy can be started. In green: definite diagnosis. ADEM = acute disseminated encephalomyelitis; AE = autoimmune etiology;
AIE = autoimmune encephalitis; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GQ1b = Ganglioside Q1b; LGI1 = leucine-rich
glioma-inactivated protein 1; NMDAR = NMDA receptor; SN-AIE = seronegative autoimmune encephalitis.
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a relapsing disease course (ADEM-optic neuritis [N = 3], and
multiphasic demyelinating encephalomyelitis [n = 1]).
Fourteen of the 68 remaining patients fulﬁlled the criteria of
probable anti-NMDAR encephalitis, of whom 11 had
NMDAR antibodies, whereas the other 3 had no NMDAR
antibodies (table 3). Of the children with anti-NDMAR en-
cephalitis, 8 children had an idiopathic etiology and 3 children
recently had HSVE.
Nine additional patients had neuronal antibodies, without
fulﬁlling the criteria of probable anti-NMDAR encephalitis.
Eight turned out to have deﬁnite anti-NMDAR encephalitis,
of which 4 with an idiopathic etiology (50%) but with less
symptoms, 3 post-HSVE (38%), and 1 girl had an ovarian
teratoma triggering the antibody production (13%). The
other patient was a 17-year-old girl with anti–acetylcholine
receptor-positive bulbar myasthenia gravis and a thymoma,
which was surgically removed. She developed severe memory
problems and mood changes within days, accompanied by
clinical signs of polyneuropathy. Laboratory results showed
AMPAR antibodies in her serum and CSF and an elevated
anti-CV2 titer in serum (>12,800). She was treated with ivMP
and IV immunoglobulins resolving both the encephalitis and
polyneuropathy.
No patient had Bickerstaﬀ brainstem encephalitis. All remain-
ing 48 children with possible AIE were tested for TPO anti-
bodies. Six of 48 children had an increased anti-TPO titer, of
whom 2 met the criteria for Hashimoto encephalopathy. One
of the other 4 patients (table 4) had diabetesmellitus type 1 and
co-occurrence of low-titer anti-glutamic acid decarboxylase 65
(anti-GAD65), considered clinically irrelevant.
Follow-up etiology of patientswith possible AIE
Nine of the 46 children (20%) were diagnosed by their
treating physician with seronegative or probable AIE,
whereas none of these children fulﬁlled the criteria of se-
ronegative AIE. Four of these 9 children had a pleocytosis in
CSF, but no MRI abnormalities in the mesial temporal lobe.
In the other 5 children, brain MRI and white blood cell
count in CSF were normal. However, complete CSF anal-
ysis, including immunoglobulin G (IgG) index and oligo-
clonal bands, was not performed.
Concerning follow-up etiology based on treating physicians’
diagnosis, these 46 children had (1) a possible AE/
inﬂammatory etiology (n = 27), (2) no support for AE/
inﬂammatory and another etiology (n = 9), and (3) no sup-
port for AIE/inﬂammatory and unknown etiology (n = 10).
After revising the data, in 6 children (22%) initially considered
as possible AE/inﬂammatory, no support for an AI/
inﬂammatory etiology was found.
Differential diagnosis of possible AIE
In table 5, exemplary cases of the included patients with AIE
and with other diagnoses are shown. These cases show
overlapping features, which may suggest AIE, but also signs
and symptoms pointing toward another diagnosis.
Discussion
This prospective observational cohort study shows that besides
anti-NMDARencephalitis andADEM, the prevalence of otherAI
encephalitides is very low in children. Furthermore, we describe
that these AI disorders show a stable incidence over the past 4
years. In addition, this study validates the criteria currently used to
diagnose AIE and shows their usefulness to detect pediatric
antibody-mediated AIE, ADEM, andHashimoto encephalopathy
in an early stage. In our cohort, a substantial number of children
were diagnosed and treated as having an AI/inﬂammatory etiol-
ogy of their neurologic symptoms, whereas in more than 20% of
them, the support for autoimmunity or inﬂammationwas lacking.
The vast majority of children with deﬁnite AIE described in this
cohort had anti-NMDAR encephalitis, whereas only 2 children
had other neuronal antibodies (anti-LGI1 and anti-AMPAR).
These antibodies have been described only sporadically in pedi-
atric cases,17 next to other neuronal antibodies, including anti-
gamma-aminobutyric acid B receptor,7 anti-gamma-aminobutyric
acid A receptor,6 anti-glycine receptor,18 and anti-GAD65.19 The
high prevalence of anti-NMDAR encephalitis in children com-
pared with the very low prevalence of other antibodies is largely
explained by epidemiologic factors. In our cohort, in more than
40% of the children with anti-NMDAR encephalitis, antibody
production was triggered byHSVE or an ovarian teratoma, both
Table 2 Demographic data and comparisons between
groups
AIE
(n = 21)
ADEM
(n = 32)
CHANCE
(n = 60) p Value
Sex, male (%) 5 (24) 19 (59) 22 (37) 0.023a
Onset age (years),
median (IQR;
range)
14 (8–16;
3–18)
4 (2–6;
1–16)
9 (5–13;
0–17)
<0.0001a
Prodromal
symptoms
13 (62%) 24 (75%) 36 (60%) 0.16
Seizures 13 (62%) 2/31 (6%) 22 (37%) <0.0001a
Immunotherapy 21 (100%) 31 (97%) 32 (53%) <0.0001a
CSF
Pleocytosis 14/19
(74%)
23/27
(85%)
9/49 (18%) <0.0001a
Protein 1/18 (6%) 3/24 (13%) 5/46 (11%) 0.76
OCB 2/3 (66%) 10/26
(38%)
2/24 (8%) 0.014
Abbreviations: AIE = autoimmune encephalitis; ADEM = acute disseminated
encephalomyelitis; CHANCE = Children’s Autoimmunity Related to Neuro-
psychiatric symptoms, Chorea and Epilepsy; IQR = interquartile range;
OCB = oligoclonal bands.
a p < 0.05.
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occurring more in children and young adults.1,20 The other
antibody-mediated AIE syndromes are not associated with these
factors and are usually idiopathic or associated with malignancy,
not occurring in childhood.11
No additional neuronal antibodies were identiﬁed in our
prospectively collected cohort of children with possible
AIE (CHANCE cohort), whereas others identiﬁed neu-
ronal antibodies in 4%–10% of children with selected
neurologic symptoms or syndromes (i.e., epilepsy21 and
demyelinating disorders22). However, pathogenicity of
most of the detected antibodies in these studies is un-
proven, including double-negative voltage-gated potas-
sium channel antibodies (anti-voltage-gated potassium
channel, without anti-LGI1 or anti-contactin-associated
protein 2) and low-titer anti-GAD65.23–25
We describe that the current guideline to diagnose AIE is of
additional value to correctly diagnose AI-related neurologic
conditions in children. One of the most important panels
in the current guideline is “probable anti-NMDAR en-
cephalitis.” If children fulﬁll these criteria, immunotherapy
can be started before deﬁnite antibody diagnosis. In our
cohort, almost 70% of children with anti-NMDAR en-
cephalitis with an idiopathic etiology could be identiﬁed by
the use of these criteria, whereas 50% of post-HSVE anti-
NMDAR encephalitis children fulﬁlled the criteria of
“probable anti-NMDAR encephalitis.” As the criteria were
meant to identify patients for initiation of treatment before
antibody results are available, the identiﬁcation of 70% of
idiopathic patients is relevant and important. The criteria
are less important in post-HSVE anti-NMDAR encepha-
litis. In most children with recent history of HSVE, de-
terioration of symptoms promptly leads to NMDAR
antibodies testing because of increased knowledge of this
syndrome.20 One-third of children with idiopathic or
paraneoplastic anti-NMDAR encephalitis did not fulﬁll the
criteria of probable anti-NMDAR encephalitis; these chil-
dren had less symptoms, and most of them had milder
disease courses than the ones who did fulﬁll the criteria.
Table 3 Patients without NMDA receptor antibodies fulfilling the criteria “probable anti-NMDA receptor encephalitis”
Sex, onset
age (years) Clinical presentation and ancillary testing Criteria
Follow-up etiology
after revision
M, 15 Flu, followed by confusion, hemiparesis and aphasia, somnolence,
and tonic-clonic seizures.
Abnormal behavior Probable AI
(Hashimoto
encephalopathy)
Anti-TPO increased 1,920 IE/mL and subclinical hypothyroidism. Speech dysfunction
FU: improvement after ivMP. Treated with levothyroxine. The disease
relapsed 2 mo later (status epilepticus), again treated with ivMP.
Seizures
Decreased level of consciousness
EEG: diffuse slowing
F, 5 Flu, followed by confusion, aphasia, focal seizures, decreased
consciousness, memory impairment, and status epilepticus.
Abnormal behavior Possible AI/
inflammatory
FU: 2 mo seizure-free after ivMP and IVIg, followed by drug-resistant
focal seizures.
Speech dysfunction
Seizures
Decreased level of consciousness
EEG: diffuse slowing
MRI: hyperintensities on T2/FLAIR bilateral
in insula, external and extreme capsule
F, 3 Flu, recurrent tonic posture of body and discomfort, developmental
regression, dysarthria, ataxia, somnolence, and chorea.
Abnormal behavior Possible AI/
inflammatory
FU: stabilization after ivMP (repeated twice). improvement inmonths. Speech dysfunction
Decreased level of consciousness
Movement disorder
EEG: diffuse slowing
CSF: pleocytosis
Abbreviations: AI = autoimmune; FLAIR = fluid attenuation inversion recovery; FU = follow-up; IVIg = IV immunoglobulin; ivMP = IV methylprednisolone;
TPO = thyroid autoantibodies.
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These ﬁndings emphasize the importance of also consid-
ering this disease in children with unexplained neuropsy-
chiatric disorders without many additional signs.
An important diﬃculty broached in this study was that in
one-ﬁfth of the children diagnosed with an AI or in-
ﬂammatory etiology, no support for autoimmunity or in-
ﬂammation was found. In many of these children,
improvement after immunotherapy was considered as a cri-
terion favoring autoimmunity. An unjustiﬁed conclusion,
because many diseases can (temporarily) respond to immu-
notherapy, or the observed response may even be the natural
course of the disease.26 However, there will always be a small
level of uncertainty, which makes it even more important to
perform complete workup in these children, MRI and CSF
analysis, including IgG index and oligoclonal bands. In the di-
agnosis of these syndromes, it is important to look for signs
and symptoms favoring autoimmunity or inﬂammation, but
the diﬀerential diagnosis of possible AIE is broad, and other
causes should also be considered, especially in children
with aspeciﬁc signs.
This study was limited because of the number of patients
included. However, it is the ﬁrst nationwide study describing
annual incidence of pediatric antibody-mediated AIE. In the
CHANCE cohort, coverage was well, but there was no na-
tionwide coverage, and childrenmay have been selected toward
an AE, as samples of patients with a higher suspicion for AE are
often referred to our center for antibody testing. Another
limitation is that inmost patients, CSF analysis was incomplete,
and oligoclonal bands and IgG index were often lacking. Oc-
casionally, this resulted in diﬃculties to adequately revise di-
agnosis. In doubt, we preferred to be cautious by diagnosing
children with an AI of inﬂammatory disorder because of the
therapeutic and prognostic implications.
From this study, we can conclude that AIE seems to be rec-
ognized properly in children. The majority of children have
anti-NMDAR encephalitis or ADEM whereas other AIE
syndromes occur only sporadically in children. The cur-
rent guideline to diagnose AIE syndromes seems to be
a useful tool to detect children with an AE of neurologic
symptoms. However, especially in children not fulﬁlling
Table 4 Patients with increased anti-TPO not fulfilling the criteria of Hashimoto encephalopathy
Sex, onset
age (years) Clinical presentation Laboratory results
Follow-up etiology
after revision
F, 16 Malaise and fever, followed by nausea, dysarthria, and ataxia. IHC: serum and CSF
negative
Possible AI/
inflammatory
Anti-NMDAR negative in
CSF
Anti-VGKC 141, anti-LGI1,
and Caspr2 negative
Anti-TPO 57
M, 9 Somnolence, apathy, fever, progressive facial weakness and respiratory problems. IHC: serum and CSF
negative
Possible AI/
inflammatory
Anti-GQ1B negative and
anti-GlyR negative
Anti-TPO 50
F, 5 Flu, followed by confusion, aphasia, focal seizures, decreased consciousness,
memory impairment, and status epilepticus.
IHC: serum and CSF
negative
Possible AI/
inflammatory
Anti-NMDAR negative in
CSF
Anti-TPO 35
F, 5 History of DM 1. Malaise, followed by recurrent attacks of delayed response,
sometimes accompanied by nonrhythmic upper limb movements.
IHC: serum and CSF
negative
No support for AI,
other etiologya
Anti-NMDAR negative in
serum and CSF
Anti-GAD65 364 IU/mL
Anti-TPO 454 IU/mL, but no
thyroid dysfunction
Abbreviations: AI = autoimmune; DM1 = diabetes mellitus type 1; GAD65 = glutamic acid decarboxylase 65; IHC = immunohistochemistry; LGI1 = leucine-rich
glioma-inactivated protein 1; NMDAR = NMDA receptor; TPO = thyroid autoantibodies; VGKC = voltage-gated potassium channels.
a Attacks related to DM1-associated hypoglycemia.
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any of the current guideline panels, it is important to be
critical before diagnosing them as having an AI or in-
ﬂammatory etiology of their neurologic symptoms. In
addition, it is essential to perform complete diagnostic
workup and to consult specialized AI/inﬂammatory ter-
tiary centers if in doubt.
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Table 5 Mimics of autoimmune encephalitis in children27
Sydenham chorea Boy (aged 16 y) presented with chorea and nocturnal agitation two weeks after laryngitis. Ancillary testing was
normal, whereas anti-DNase titer was increased (298 IE/mL). Cardiac ultrasound showedmitral valve
regurgitation. He was treated with ivMP and penicillin.
Neuropsychiatric systemic lupus
erythematosus
Girl (aged 16 y) with ANA, anti-ENA, anti-RNP, and anti-dsDNA-positive polyarthritis and neutropenia, had
memory problems and behavioral changes, followed byhypersomnia and reduced awareness. She was suspected to
have bacterial meningitis. CSF showed a mild pleocytosis. Because of negative cultures, she was treated with ivMP,
oral steroids, and mycophenolate mofetil. She recovered after ivMP. The disease relapsed 2 y later.
Rasmussen encephalitis Boy (aged 6 y) developed daily focal seizures with impaired awareness and behavior arrest. He had over 20 focal
seizures a day, refractory to antiepileptic treatment, combinedwith aggressive behavior. HisMRI showed lesions in
the right hemisphere and atrophy. CSF analysis was normal. He was treated with ivMP and responded. He had
a hemispherectomy 6mo later because of recurrent seizures, and he is seizure-free since. Pathology examination
showed infiltration of T lymphocytes and cavitation in the cortex.
PANDAS Girl (aged 10 y) developed a complex motor tic disorder and childish behaviorwith overnight explosion 1mo after
laryngitis. Ancillary testing showed an increasedAST (400 IE/mL) andpositive throat culture for Streptococcus. She
was treated with IVIg, which reduced the tics only moderately. She was treated with clonidine and with amoxicillin
for 5 y. Her tics improved, but worsen during illnesses.
Klein Levine syndrome Girl (aged 16 y) fell of a horse. Three days later, she developed disinhibited behavior and hypersomnolence. MRI
and CSF analyses were normal. She recovered within 5 wk without treatment. Seven months later, she had
a comparable episode after a cold; again, symptoms were reversible.
Narcolepsia Girl (aged 9 y) developed excessive daytime sleepiness, emotional behavior, irritability, and collapses while
being emotional, after scarlet fever. MRI and CSF analyses were normal. Hypocretin-1 was absent is CSF, and
a multisleep latency test showed severe daytime sleepiness. She was treated with sodium oxybate and is doing
well since.
Gilles de la Tourette Boy (aged 10 y) developed motor facial tics and vocal tics, hyperactive behavior, and irritability. Brain MRI was
normal. He was not treated and has a stable disease, but tics worsen during illness.
Hashimoto encephalopathy Boy (aged 15 y), had acute confusion, aphasia, central facial palsy, and a right-sided sensory disorder. He was
treated with thrombolysis because of suspicion of cerebral ischemia. MRI was normal and showed no
abnormalities on DWI. He developed focal seizures and status epilepticus. EEG showed sharp activity parieto-
temporo-occipital. Hewas treatedwith ivMPbecause of an increased anti-TPO titer (1,920 IE/mL) and subclinical
hypothyroidism. He recovered completely, but disease relapsed 2 mo later.
Abbreviations: ANA = anti-nuclear antibody; AST = anti-streptolysin titer; dsDNA = double stranded DNA; DWI = diffusion-weighted imaging; ENA = extractable
nuclear antigen; IVIg = IV immunoglobulin; ivMP = IV methylprednisolone; PANDAS = Pediatric Autoimmune Neuropsychiatric Disorders Associated with
Streptococcal Infections; RNP = ribonucleoprotein; TPO = thyroid autoantibodies.
Italic: signs or symptoms that can point toward autoimmune encephalitis.
Bold: signs and symptoms contributing to another diagnosis.
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